
News
Filter Results
Displaying 61–70 of 506
-
Apr 3, 2024
The Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund hosted their annual Investing in Cures Summit (ICS) on March 8 and 9, 2024, to highlight the progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Mar 26, 2024
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
The company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Mar 25, 2024
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 15, 2024
The May 9th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Feb 13, 2024
The free, online event on March 20, 2024, will feature presentations from Rachel Huckfeldt, MD, PhD, Mass Eye and Ear, and Rachelle Lin, OD, Ketchum University.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 6, 2024
Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy
Gyrate atrophy is an inherited retinal disease—causing progressive vision loss. GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
-
Feb 1, 2024
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
ACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.